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Associations between the gut microbiota
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Collin M. Spencer2, Susan V. Lynch2, Scott S. Zamvil2, Emmanuelle Waubant2 and US Network of Pediatric MS Centers
Abstract
Background: As little is known of association(s) between gut microbiota profiles and host immunological markers, we
explored these in children with and without multiple sclerosis (MS).
Methods: Children ≤18 years provided stool and blood. MS cases were within 2-years of onset. Fecal 16S rRNA gene
profiles were generated on an Illumina Miseq platform. Peripheral blood mononuclear cells were isolated, and Treg
(CD4+CD25hiCD127lowFoxP3+) frequency and CD4+ T-cell intracellular cytokine production evaluated by flow
cytometry. Associations between microbiota diversity, phylum-level abundances and immune markers were
explored using Pearson’s correlation and adjusted linear regression.
Results: Twenty-four children (15 relapsing-remitting, nine controls), averaging 12.6 years were included. Seven were
on a disease-modifying drug (DMD) at sample collection. Although immune markers (e.g. Th2, Th17, Tregs) did not
differ between cases and controls (p > 0.05), divergent gut microbiota associations occurred; richness correlated
positively with Th17 for cases (r = +0.665, p = 0.018), not controls (r = −0.644, p = 0.061). Bacteroidetes inversely
associated with Th17 for cases (r = −0.719, p = 0.008), not controls (r = +0.320, p = 0.401). Fusobacteria correlated
with Tregs for controls (r = +0.829, p = 0.006), not cases (r = −0.069, p = 0.808).
Conclusions: Our observations motivate further exploration to understand disruption of the microbiota-immune
balance so early in the MS course.
Keywords: Pediatric multiple sclerosis, Gut microbiota, 16S rRNA, Case–control study, Risk factors, Immune markers,
Disease-modifying drugs, Microbiota-immune balance
Background
Multiple sclerosis (MS) is thought to be an autoimmune
disease in which components of the immune system tar-
get cells in the brain and spinal cord, resulting in demye-
lination and axonal damage. While the cause(s) are
unknown, both genetic and early life environmental ex-
posures are implicated. Emerging studies have shown
perturbations in the gut microbiota of individuals with
MS relative to controls [5, 22, 27]. The gut microbiota’s
role in modulating the host’s immune system could be
highly relevant for MS. However, unlike the well-studied
relationship between the immune system and MS dis-
ease processes, little is known of the gut microbiota-
immune relationship in MS. The gut microbiota appears
highly influential in stimulating a pro-inflammatory T
cell response and subsequent disease in animal models
of MS [4, 17]. Further, perturbations to the gut micro-
biota composition (dysbiosis) have been linked to other
immune-mediated diseases distal from the gut, including
rheumatoid arthritis, type 1 diabetes, atopic dermatitis
and asthma [20]. These conditions could all have their
‘pathogenic origins’ in the immune response modulation
by the microbiota [20].
Compared to adult MS, pediatric MS represents a
unique opportunity to examine such associations close
to the original exposures and biological onset of disease.
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Further, children have had a limited lifetime of expo-
sures, and hence fewer potential confounding effects.
We conducted a pilot study to explore the association(s)
between the gut microbiota and blood immunological
markers in disease-modifying drug (DMD) naïve and ex-
posed pediatric MS cases early in their disease course
and healthy controls.
Methods
Children ≤18 years old accessing a general or MS spe-
cific pediatric clinic at the University of California, San
Francisco (UCSF), USA were invited to participate in an
environmental risk factor study; those providing both a
stool and blood sample formed the current study cohort.
MS cases had <2 years of disease (from symptom onset).
Controls were similar for age and sex, were not known
to have any autoimmune disorders (except for asthma or
eczema) and had neither parent diagnosed with MS nor
a related disorder. No child was exposed to a systemic
antibiotic in the 2 months prior to stool collection.
Cohort characteristics were obtained from participants
via questionnaires, and standardized forms completed by
the physician or research coordinator (JH) supported by
chart abstraction, as described previously [27]. The
UCSF Institutional Review Board approved the study.
All subjects and a parent signed an assent/consent form.
Stool collection, DNA extraction and 16S rRNA profiling
Participants were asked to collect and ship overnight (on
ice) a sample of the child’s first stool of the day to UCSF
where it was stored at −80 °C. DNA was then extracted
from approximately 25 mg of stool using PowerSoil® DNA
Isolation Kit (MO BIO Laboratories, Inc, Carlsbad, CA)
prior to amplification of the V4 hypervariable region of
the bacterial 16S rRNA gene was amplified in triplicate
[7]. Amplicons were combined, purified and pooled in
equimolar concentrations and sequenced using a Miseq
platform (Illumina, Inc., San Diego, CA) with a 251×151
base pair run. The 16S rRNA reads were grouped using a
≥97 % similarity threshold into operational taxonomic
units (OTUs, i.e., ‘taxa’), which were singly rarefied to
201,546 reads per sample. Taxonomy was assigned using
the Greengenes database via the QIIME (Quantitative In-
sights Into Microbial Ecology) [6, 9] platform. Community
alpha diversity was expressed as richness (the number of
unique taxa identified); evenness (taxon distribution), and
Faith’s phylogenic diversity metric (which weights phylo-
genetic (i.e. evolutionary) relationships between taxa) [8],
using the Vegan and Picante packages (R software [24]),
Additional file 1: Appendix 1, supplementary methods.
Blood immune markers
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient separation (Ficoll-Paque, GE
Healthcare), and cryopreserved on the day of collection.
Thawed PBMCs were allowed to recover in culture over-
night, and then plated at 1.5 × 106 cells/ml in X-VIVO
15 media (ThermoFisher), supplemented with 5 %
human AB serum (Life Technologies). Cells were stimu-
lated with PMA (50 ng/ml) + ionomycin (0.5 μg/ml), or
media alone, for 5 h in the presence of brefeldin A
(GolgiPlug, BD Biosciences). Treg frequency and
intracellular cytokine production by T cells were eval-
uated by flow cytometry. Treg (CD4+CD25hiCD127low-
FoxP3+) frequency was expressed as a proportion of
total CD3+ T cells. Frequencies of the following CD4+ T
cell subsets were quantitated as: Th1 (IFN-γ+), Th17
(IL-17+), Th2 (IL-4+), and Tr1 (IL-10+). Total (CD3+)
T cells and CD4+ T cells were reported as proportions
of PBMC and total T cell populations, respectively.
Statistical analyses
Cohort characteristics were presented descriptively.
Blood immune markers were compared between con-
trols and cases (all cases, then DMD naïve and exposed
separately) using non-parametric tests (Mann–Whitney
and Kruskal-Wallis tests) and associations with the gut
microbiota metrics (alpha diversity and phylum-level
abundances) were initially explored via Pearson’s correl-
ation coefficient. Where associations were at least ‘mod-
est [12]’ and significant (absolute r > 0.5 and p < 0.05),
linear regression analyses were performed, with the gut
microbiota metrics the independent and immune
markers the dependent variables, adjusting for age, dis-
ease duration, DMD exposure or case or control status,
as appropriate (Additional file 1: Appendix 1). Adjusting
factors were selected based on clinical relevance (i.e.,
disease duration, DMD exposure) and/or the limited
pediatric literature which indicated that age [13] and
DMD exposure [27] could influence the relationship be-
tween the developing gut microbiota and immune system.
Due to the small sample size, exploration of relationships
at the taxon level was not performed for this study. No
corrections were applied for multiple testing, although the
expected number of chance findings from the Pearson’s
correlations performed were estimated as follows: seven
immune markers were assessed for correlation with three
diversity metrics and 13 phyla, resulting in 7×3 = 21 tests
and 7×13 = 91 tests, respectively. Chance significance
would be expected for one in 20 tests, i.e. approximately
one test (diversity) and 4–5 tests (phylum-level). Statistical
analyses were performed using the Statistical Package for
the Social Sciences (SPSS for Windows, Ver. 22.0.
Armonk, NY: IBM Corp. 2013).
Results
Twenty-four children (15 relapsing-remitting MS cases,
nine controls) with a mean age of 12.6 years (SD = 4.18;
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range 4–18) fulfilled criteria and provided both stool
and blood samples; 9/24 (38 %) were boys. All cases met
McDonald criteria, had relapsing-remitting MS and a
short disease duration (mean = 10.0 months; range 2–23
months at stool collection). The mean age at MS onset
was 11.5 years (SD = 4.84; range 4–17); seven (47 %) MS
cases were exposed to a DMD and five (33 %) a cortico-
steroid (in the 2 months pre-stool sample). Although
more controls self-identified as white (67 % controls,
33 % cases) and controls averaged almost 2 years older
than cases, the proportions over 12 years were rather
similar (56 % and 60 % respectively) and no characteris-
tic (Table 1) differed significantly between cases and
controls (all p > 0.2, not shown). Additional demo-
graphic, lifestyle and clinical characteristics are shown in
Table 1 and Additional file 1: eTables 1.1 and 1.2, includ-
ing the annualized relapse rate (mean = 0.91; SD = 0.851),
time since last relapse (mean = 181.1 days; SD = 142.17)
and dietary metrics (fat/fibre groupings) which were simi-
larly distributed between cases and controls. All stool
samples were collected within 3 months of the blood draw
(median = 13.5 days; range 0–85 days). Most stool samples
(n = 21) were collected after the blood draw, two before
and one on the same day.
For the Treg analyses, 24 samples were available (n = 9
controls; n = 15 MS cases [8/15 were DMD naïve]).
For the intracellular cytokine analyses, 21 samples
were available (n = 9 controls; n = 12 MS cases [6/12
were DMD naïve]).
Comparison of cases and controls: gut microbiota and
blood immune markers
Similar to that reported in our prior gut microbiota
study [27] (from which the current cases and controls
were a sub-set), there were no differences between
cases (all cases as well as DMD exposed or naïve
cases) and controls for any of the alpha diversity metrics
(Additional file 1: eTable 2). While there were no signifi-
cant differences when all cases were compared to controls
for the immune markers (p > 0.05, Additional file 1:
eTable 2), some differences depending on DMD expos-
ure status were observed (Additional file 1: eTable 2).
Hence, where possible, DMD exposure was considered
in the analyses, either through model adjustment or a
separate model developed.
Microbiota diversity-immune associations
While there were similarities for both cases and con-
trols in the associations between their gut microbiota
diversity metrics and host immunological markers, diver-
gence was also apparent (Table 2, Fig. 1 and Additional file
1: eTable 3.1).
For controls, gut microbiota diversity was predomin-
antly inversely associated with Th2 and Th17. However
for cases, there were either no, or modest positive associa-
tions with Th2 and Th17, respectively (Table 2 and Fig. 1).
After model adjustments, both immune markers remained
significantly associated with evenness for the controls
(age-adjusted p < 0.05, Additional file 1: eTable 3.1),
Table 1 Characteristics of the pediatric multiple sclerosis (MS) cases and controls
Characteristic, n (%) unless stated otherwise MS cases, n = 15 Controls, n = 9 Cases and controls, n = 24
Sex
Girl 8 (53 %) 7 (78 %) 15 (63 %)
Boy 7 (47 %) 2 (22 %) 9 (38 %)
Age at stool sample collection, years: mean (SD; range) 11.9 years (SD = 4.64; 4–17) 13.8 years (SD = 3.19; 9–18) 12.6 years (SD = 4.18; 4–18)
Age at stool sample collection
≤ 12 years old 6 (40 %) 4 (44 %) 10 (42 %)
> 12 years old 9 (60 %) 5 (56 %) 14 (58 %)
Race
White 5 (33 %) 6 (67 %) 11 (46 %)
Non-white 10 (67 %) 3 (33 %) 13 (54 %)
Ethnicity
Hispanic 6 (40 %) 3 (33 %) 9 (38 %)
Non- Hispanic 9 (60 %) 6 (67 %) 15 (63 %)
Co-morbid conditiona
Present 6 (40 %) 2 (22 %) 8 (33 %)
Absent 9 (60 %) 7 (78 %) 16 (67 %)
Key: SD standard deviation
aComorbid conditions were collected pre-stool sample (but were not necessarily present pre-MS onset): for cases: headache (n = 1); atopic dermatitis/eczema
(n = 1); long-term constipation (n = 1); history of seizures (n = 1); reactive airways disease and headache (n = 1); scoliosis (n = 1). For controls: kyphosis (n = 1);
Raynaud phenomenon (n = 1)
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indicating that gut microbiota dominated by specific
taxa were associated with increases in these immune
markers. For the cases, both richness and Faith’s diver-
sity metric remained positively associated with Th17
(disease duration adjusted only, p = 0.008 and p = 0.013,
respectively; p > 0.05 when age or DMD-adjusted,
Additional file 1: eTable 3.1).
While positive associations were observed between the
gut diversity metrics and Tregs, CD4+ T cells and Tr1 for
both cases and controls, the strength and level of signifi-
cance varied, often being more pronounced for the MS
cases (Table 2). After model adjustments, significant asso-
ciations remained with CD4+ T cells and Tr1 for cases
only (the former when disease duration or DMD adjusted,
the latter when age or disease duration but not DMD
exposure adjusted). Tregs were the most strongly asso-
ciated for the DMD exposed cases (evenness, r = 0.851,
p = 0.015) which remained significant after age or dis-
ease duration adjustments (p = 0.034 and p = 0.017, re-
spectively, Additional file 1: eTable 3.1).
For both cases and controls, no remarkable associations
were observed between the gut microbiota diversity
metrics and total T cells and Th1 (both p > 0.05; not all
data shown).
Microbiota phyla-immune associations
Bacteroidetes abundance was inversely correlated with
several blood immune markers for cases and controls
(Table 3). Both CD4+ T cells and Tregs remained inde-
pendently associated, regardless of age or DMD exposure
(all adjusted p < 0.05, Additional file 1: eTable 3.2). Cases
in particular exhibited strong, negative associations be-
tween Bacteroidetes abundance and immune markers
such as CD4+ T cells, Tregs and Th17 (r ranged from
0.613 to 0.719, all p < 0.02). All were independent of DMD
exposure, and disease duration (p < 0.02, Additional file 1:
eTable 3.2). Although only Tregs remained significant
after age adjustment (p = 0.042).
In contrast, positive correlations (modest or strong)
were observed for controls for Th1 and Th2 (r > 0.69,
p = 0.034 and p = 0.039, Table 3). However, neither
remained significant after age adjustment (p > 0.05,
not shown).
Table 2 Associations between the gut microbiota alpha diversity metrics and peripheral blood immune markers and: all children,
cases and controls
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Actinobacteria abundance was positively associated
with several blood immune markers for both cases and
controls. The strongest being with Tr1 and CD4+ T
cells; both were independent of age or DMD (p < 0.005,
Additional file 1: eTable 3.2). However, the abundance
of Fusobacteria was positively associated with Tregs for
controls only (age adjusted p = 0.009, Additional file 1:
eTable 3.2), with no evidence of a relationship (positive
or negative) for cases (Table 3).
The Firmicutes-immune associations were mixed
(Table 3); divergence between cases and controls in-
cluded strong positive association with Th17 for cases only
(independent of disease duration or DMD exposure, both
adjusted p-values were <0.05, but not age, p = 0.089). Con-
versely for controls (not cases), strong inverse associations
with Th1 (r = −0.789, p = 0.011) were observed, remaining
significant after age adjustments (p < 0.03, Additional
file 1: eTable 3.2).
Discussion
Associations were found between the composition of the
gut microbiota and the host blood immune marker pro-
files in children with and without MS. While there were
similarities for both cases and controls, there were also
several divergent findings which were independent of
DMD exposure. Further, these divergent microbiota-
immune relationships were measurable very early in the
MS disease course, as all pediatric cases were within
24 months of symptom onset. Disruption of microbiota-
immune balance so early in MS is intriguing.
Fig. 1 Divergence was observed for cases and controls in the associations between gut microbiota alpha diversity indices and peripheral blood
immune markers: Gut diversity was negatively associated with Th17 in control children, but positively associated in cases. Richness is depicted for
illustrative purposes. Pearson’s correlation coefficient and p-values for all children, controls, cases and by DMD exposure
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Gut microbiota evenness was strongly and inversely
associated with Th17 and Th2 for the control children.
However, there was either no or modest positive associa-
tions for the MS cases. While we were unable to find a
similar study with which to compare our findings, a
recent Canadian study demonstrated that diversity de-
pleted uneven neonatal gut microbiota preceded later
childhood-onset atopy and asthma risk [2]. In addition,
mono-colonization i.e. an uneven community of the
murine gut microbiota with segmented filamentous bac-
teria results in significant expansion of ileal lamina pro-
pria Th17 populations [15]. Our observations were
consistent with these studies and suggest that uneven
microbiota (which can indicate species overgrowth) in
the pediatric gut is associated with increases in markers
of Th17 and Th2 populations. Why this microbiota-
immune relationship is reversed or lost in the MS chil-
dren is of interest and may be due to the specific
Table 3 Association between the gut microbiota’s phylum-level abundance and peripheral blood immune markers
aimmune markers were available for all 24 children, except as follows:: for Th17 and Th1 (n = 21 children; n = 9 controls, n = 12 cases [6 DMD exposed, 6 DMD naïve]); for
Tr1 and Th2 (n = 20 children; n = 8 controls, n = 12 cases [6 DMD exposed, 6 DMD naïve])
No correction for multiple testing. Seven immune markers were assessed for correlation with three diversity metrics and 13 phyla, resulting in 7 × 3 = 21 tests (Table 2)
and 7 × 13 = 91 tests (Table 3) respectively. Chance significance would be expected for 1 in 20 tests, i.e. approximately 1 test (diversity) and 4–5 tests (phylum-level)
Remaining blood immune markers (total T cells) and phyla (Verrucomicrobia, Proteobacteria, Euryarchaeota, Tenericutes, Cyanobacteria, Deferribacteres, Synergistetes,
TM7 and Lentisphaerae) are not shown here due to few significant findings and/or low abundances for the phyla. Except as follows
For all children: Lentisphaerae and Tregs (r = 0.427, p = 0.037); TM7 and total T cells (r = −0.590, p = 0.002)
Cases: Lentisphaerae and Tr1 (r = 0.703, p = 0.011); TM7 and total T cells (r = −0.628, p = 0.012)
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composition of gut microbial communities in MS versus
control populations.
Nonetheless, there were also similarities for the cases and
controls in that both groups exhibited positive associations
between the gut microbiota diversity metrics and Tregs,
CD4+ T cells and Tr1. Not all findings were independent of
age which may be suggestive of an evolving microbiota-
immune relationship as the child develops [16]. Also,
although the direction of effect was similar for cases and
controls, the strength of these associations were greater for
the MS cases in a number of instances, particularly for the
DMD exposed group. For instance, despite no significant
differences between controls and cases (DMD exposed or
naïve) for Tregs, this immune marker was strongly associ-
ated with diversity (evenness) for the DMD exposed
cases (i.e. had a high r-value: r = 0.851, p = 0.015) which
was independent of age or disease duration (p < 0.05).
Microbiota phylum abundance-immune associations
There were several microbiota-immune associations
measurable at the phylum-level which were consistent
across both cases and controls. These included Bacteroi-
detes and Actinobacteria which represent two of the
most common bacterial phyla in the human gut. The
relative abundance of Bacteroidetes was negatively asso-
ciated with both CD4+ T cells and Tregs, and strong
positive associations were observed between Actinobac-
teria and CD4+ T cells and Tr1, all of which were inde-
pendent of age or DMD exposure. These observations
concur with the wider literature. For instance, Bacteroi-
detes includes species such as Bacteroides fragilis, well
studied in animal models for their ability to induce CD4
+ T cells [20, 21]. In addition, Tr1, i.e. IL-10 are reported
as one of the main immunoregulatory factors required
for immune tolerance of the intestinal microbiota [20],
such that a strong relationship with one of the main gut
phyla would not be unexpected.
However, divergences in the phylum-immune relation-
ship were observed. Of interest were two associations
only observed in the control children; Fusobacteria
abundance exhibited a strong, positive association with
the Tregs and the Firmicutes phylum was inversely asso-
ciated with Th1 (r = 0.829 and r = −0.789, respectively,
p < 0.02). Both were independent of age. Conversely,
for cases, no strong relationships (either positive or
negative) were observed between these phyla and im-
mune markers. These differences are likely due to the
specific composition of these phyla, each of which
consists of hundreds of functionally distinct species
and strains. For example members of Clostridiales
Clade IV and XIV can induce Treg cells [3] while a
related Firmicute, Clostridium difficile is a well described
human pathogen. Findings highlight the need to study
much larger cohorts, sufficiently powered to identify spe-
cific gut microbiome members that exhibit relationships
with these important adaptive immune responses.
While little is known of the gut-related Fusobacteria-
immune relationships, there is some evidence to suggest
that dysregulation of Tregs may contribute to disease
processes in MS, specifically an increased risk of relapse
[25]. Loss of the Fusobacteria-immune relationship for
cases may be clinically relevant and possibly linked to
our previous observation that depletion of Fusobacteria
in the gut microbiota of pediatric MS cases was associated
with a higher risk (hazard) of relapse [26]. It would be of
value for future studies to examine the gut-immune rela-
tionship in the context of MS disease activity (i.e., clinical
relapses or MRI-related metrics).
Possible mechanisms of action
While we modelled the gut microbiota as a predictor of
host immune markers, the two are considered to have
coevolved with likely a bi-directional relationship [18].
Although the potential mechanism(s) of action are not
well understood [1], the gut microbiota are known to
elicit Treg recruitment, regulate Th17 and Treg cell
differentiation, which in the healthy gut promotes
immune-microbiota homeostasis [19]. Metabolites
produced by the gut microbiota such as short chain fatty
acids (e.g., butyrate) have been shown to exert immuno-
modulatory affects, including down-regulation of pro-
inflammatory mucosal Th2 responses [1, 10, 19, 28]. As
suggested by our findings, and others, the effects of
microbiota compositional changes are not exclusively
local, but can influence the systemic immune re-
sponse and, as others have shown, are associated with
systemic inflammatory diseases distal to the gut, such
as rheumatoid arthritis [19]. In the context of condi-
tions such as inflammatory bowel disease, others have
concluded that ‘dysregulated CD4 T cells responses to
antigens of the microbiota leads to chronic, typically
relapsing and remitting disease that reflects the im-
mune system’s inability to eliminate the antigens that
drive the abnormal response [20].’ This could apply
to MS, also a predominantly relapsing-remitting dis-
ease. Evidence to suggest that gut microbiota can trig-
ger non-gut related diseases includes the observation
that Clostridia sp., Candidatus arthromitus or seg-
mented filamentous bacteria in mice can cause in-
flammatory arthritis [19] and MS-like symptoms in
EAE [17] mediated via Th17 production.
Strengths and limitations
Limitations of this pilot study include the small sample
size and no correction for multiple testing. Some find-
ings would be expected by chance alone, such that we
have specifically focused on those that were modest or
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strong and significant (absolute r > 0.5 and p < 0.05), ap-
peared consistent across related biological markers and,
wherever possible, developed models adjusting for po-
tential confounders. In addition, we purposely focused
on a high-level view of the gut microbiota, i.e., diversity
and phylum-level abundance. Our findings require repli-
cation, but are also necessary to help guide and power
future studies. Further exploration is needed, when the
sample size permits, such as: to understand the specific
functions being performed by the gut microbiota, or key
members of the community present; to gain a better un-
derstanding of the influence of a child’s age on the
microbiota-immune relationship; and to examine the in-
fluence of host genetics [11], diet, drug exposure and
other effect modifiers.
Strengths include a well-phenotyped group of children
with a rare but life changing chronic condition; less than
5 % of individuals with MS develop the disease and are
diagnosed during the childhood years. All MS cases were
examined and diagnosed by a pediatric MS neurologist
and enrolled close to symptom onset with paired stool
and blood samples collected within a short time of each
other. Our study offers novel insights; the gut microbiota
has not been well characterized in children (e.g. the
Human Microbiome Project, HMP only included
adults over 18 years [14]). Further, we are not aware
of another study exploring the microbiota-immune re-
lationship in MS (adults or children).
Conclusions
Understanding the relationship between diseases consid-
ered immune-mediated, such as MS, and the gut micro-
biota, which has a central role in shaping the immune
response, is fundamental [20]. We found associations be-
tween the gut microbiota composition and host blood
immune markers which were divergent between cases
and controls. Why the microbiota-immune balance ap-
pears disrupted in MS is intriguing and deserves further
study. A better understanding and identification of key
microbiota members involved may lead to novel oppor-
tunities to modulate immune dysregulation in diseases
such as MS.
Additional file
Additional file 1: Supplementary Methods (Appendix 1) and eTables 1
to 3.2 [23, 29, 30]. (DOCX 38 kb)
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